Robert Neer, M.D.
	Dr. Neer is a professor at Harvard Medical School and an endocrinologist at the Massachusetts General Hospital, where for 16 years he has directed the Osteoporosis Center and the Bone Density Center. For 22 years prior to that, he directed the Metabolic Research Center and its successor, the Mallinckrodt General Clinical Research Center, at Massachusetts General Hospital. Dr. Neer has 40 years experience as a clinical and small animal researcher in the field of bone mineral metabolism and metabolic bone disease, and has conducted pioneering translational research with human parathyroid hormone 1-34, salmon calcitonin, 1,25-dihydroxy vitamin D3, and 1-alpha hydroxy vitamin D3. His laboratory first demonstrated the superiority of dual-energy x-ray absorptiometry (DXA) as a method for diagnosing osteoporosis, and first introduced this technology into clinical medicine, where it is now the gold standard. Dr. Neer is a former member and former chairman of the U.S. Food and Drug Administration's Endocrine and Metabolic Diseases Advisory Committee, and has been a consultant to multiple U.S. and foreign international pharmaceutical companies, and multiple U.S. and foreign biotechnology start-up companies. He has extensive experience with human parathyroid hormone 1-34, and helped Eli Lilly, Inc. plan its successful Phase I, Phase II, and Phase III clinical development of this compound.
	Robert Lindsay, M.B., Ch.B., Ph.D., F.R.C.P.
	Dr. Robert Lindsay is Chief of Internal Medicine at Helen Hayes Hospital and Director of its Clinical Research Center. A Professor of Clinical Medicine at Columbia University, Dr. Lindsay has authored over three hundred journal articles, abstracts, and book chapters on osteoporosis and estrogen replacement therapy. He is a graduate of the University of Glasgow, where he received his BSc, M.B.Ch.B., Ph.D., and F.R.C.P. Dr. Lindsay completed an internship and residency in Medicine at the Western Infirmary, and an internship in Surgery at the Southern General Hospital, both in Glasgow. He is an Accredited Specialist in Internal Medicine and Endocrinology with the Royal College of Physicians, a Fellow of the American College of Nutrition, a Fellow of the American College of Endocrinology, a Fellow of the Royal Society of Medicine, and a Fellow of the Royal College of Physicians and Surgeons. Dr. Lindsay is a member of the American Society for Bone and Mineral Research from whom he received the Bartter Award for excellence in clinical research in 1997. He is also a member of the Endocrine Society and the American College of Physicians and is an Editor of Osteoporosis International. He is past President of the National Osteoporosis Foundation and is the 1999 recipient of the Foundation's Scientific Leadership Award
	Toshio Matsumoto, M.D., Ph.D.
	Dr. Matsumoto is a professor and chair of the Department of Medicine and Bioregulatory Sciences at the University of Tokushima Graduate School of Medical Sciences, a position he has held since 1996. He is also currently Dean of the University of Tokushima’s School of Medicine and Graduate School of Medical Sciences. Previously Prof. Matsumoto held several teaching positions at the University of Tokyo School of Medicine. He holds an M.D. and Ph.D. from the University of Tokyo School of Medicine and completed a postdoctoral fellowship in the Department of Internal Medicine and Cell Biology at Yale University School of Medicine. He is Associate Editor of BONE, Journal of Bone and Mineral Metabolism (Tokyo). Prof. Matsumoto is currently conducting research on myeloma and cancer-induced bone diseases, regulation of bone formation by mechanical stress and parathyroid hormone, and vitamin D and steroid hormones in the regulation of bone remodelling.

	Sophia Ish-Shalom, M.D.
	Professor Ish-Shalom is Head of the Metabolic Bone Diseases Unit at Rambam Medical Center in Haifa, Israel, a position she has held since 1995. She is also an Associate Professor of Endocrinology at the Bruce Rappaport Faculty of Medicine at the Technion-Israel Institute of Technology. She holds an M.D. from the Technion-Israel Institute of Technology and is Board certified in both Internal Medicine and Endocrinology in Israel. Prof. Ish-Shalom has over 30 years of clinical and research experience in Israel and Canada and has published over 40 articles on osteoporosis research in leading scientific journals. Her research interests include anabolic treatment of osteoporosis with PTH or its fragments, nutritional aspects of osteoporosis, secondary osteoporosis, quantitative ultrasound and treatment of severe osteoporosis. She is a member of the committee of the Israeli Endocrine Society and the Israeli Foundation for Osteoporosis and Bone Diseases as well as Head of the Israeli Association of Medical Women. She also heads the Committee on Diagnosis and Treatment of Osteoporosis at the Israeli Ministry of Health, and is a member of the American Society for Bone and Mineral Research and the American Endocrine Society.
	Claus Christiansen, M.D
	Claus Christiansen, M.D, A Synarc co-founder, the original CCBR (Center for Clinical and Basic Research) founder, and the Executive Director of Nordic Bioscience, Denmark. Over the past 30 years, he has published extensively in the field of calcium metabolism, particularly regarding osteoporosis in postmenopausal women, as well as in the field of cardiovascular disease. CCBR and Dr Christiansen are world-famous for high-quality clinical trials and for their important contributions to basic and clinical research. Professor Christiansen has published extensively in the field of osteoporosis with over 800 articles and book chapters, particularly in the area of calcium metabolism in postmenopausal women. He has been Chairman of several international symposia on osteoporosis, and has been an invited speaker on calcium metabolism at almost all international meetings in the field. He is also a member of the Editorial Boards of the journals Bone and Osteoporosis International

© TransPharma Medical™ Ltd. All Rights Reserved.
updated May 2008